updated 7/15/2004 6:48:05 PM ET 2004-07-15T22:48:05

The Food and Drug Administration is revamping how it reviews drugs to treat, diagnose and prevent cancer, hoping to speed evaluation of the products.

  1. Don't miss these Health stories
    1. Splash News
      More women opting for preventive mastectomy - but should they be?

      Rates of women who are opting for preventive mastectomies, such as Angeline Jolie, have increased by an estimated 50 percent in recent years, experts say. But many doctors are puzzled because the operation doesn't carry a 100 percent guarantee, it's major surgery -- and women have other options, from a once-a-day pill to careful monitoring.

    2. Larry Page's damaged vocal cords: Treatment comes with trade-offs
    3. Report questioning salt guidelines riles heart experts
    4. CDC: 2012 was deadliest year for West Nile in US
    5. What stresses moms most? Themselves, survey says

Under the restructuring, a new Office of Oncology Drug Products will oversee both traditional chemotherapies and biologically based treatments, as well as imaging agents to diagnose cancer and the new field of cancer prevention drugs.

The hope is that having everything under one roof not only could speed evaluation, but ensure they’re all held to the same scientific standards.

“We are committed to creating the most effective and efficient review process possible to ensure life-saving treatments are made available to cancer patients,” said Health and Human Services Secretary Tommy Thompson, who will announce the reorganization on Friday.

Officials couldn’t quantify how much faster evaluations could be made. Cancer treatments already get quick reviews within FDA; one was cleared in a record seven weeks.

© 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments